Entries by Hanna Frykman

The Immunotoxicity testing in the 21th century seminar

Welcome to the seminar Immunotoxicity testing in the 21th century – recent developments within prediction of immunotoxicity using alternative methods. The seminar will take place at the Medicon Village Aula (Hörsalen) on November 23, 2017 with the support from SenzaGen and Medicon village Program: 13.15-13.30     Welcome Prof. Malin Lindstedt, Dept. of Immunotechnology Kerstin Jakobsson, Vice […]

SenzaGen presenterar vid Vator Securities Unicorn Summit den 14 november 2017

SenzaGen meddelar att bolaget deltar i Vator Securities Unicorn Summit, vilken äger rum i Stockholm. Vd Anki Malmborg Hager kommer ge en presentation av SenzaGens pågående och planerade aktiviteter inom utvecklingen och kommersialiseringen av GARD – en teknologiplattform som gör det möjligt att ersätta djurförsök med genetiska tester i provrör för att bedöma om de […]

We are hiring a Communication Specialist

Job advert This is an opportunity to join an exciting Life Science startup, contribute to the continued development of its communication platform and build brand awareness for the company and its products. Listed on Nasdaq First North (SENZA) SenzaGen is headquartered in Lund, Sweden with a subsidiary in Davis, California, USA. With its technology platform […]

Forskningsarbete kring GARDprotein publicerat i välrenommerad vetenskaplig tidskrift

SenzaGen meddelar att forskningsresultat som stödjer utvecklingen av ett nytt applikationsområde för företagets testplattform GARDTM publicerats i den välrenommerade tidskriften Toxicology in Vitro. Det forskningsarbete som beskrivs i publikationen utgör basen för GARDprotein – en testmetod som utvecklas för att kunna utesluta allergiframkallande proteiner ur dagens och morgondagens livsmedel.  I publikationen, An alternative biomarker-based approach for the […]

Research on GARDprotein published in highly reputed scientific journal

SenzaGen announces that research findings that support the development of a new application area for the company’s test platform GARDTM have been published in the highly reputed journal Toxicology in Vitro. The research described in the publication constitutes the basis of GARDprotein – a test method currently being developed to be able to eliminate allergy-inducing […]

SenzaGen CEO Anki Malmborg Hager presents at Swetox conference on future research without animal testing

SenzaGen’s CEO, Anki Malmborg Hager, gives a presentation today on October 17, entitled: A new, animal-free allergy test with the goal of becoming a “golden standard” for risk assessment in the cosmetics and chemical industry. An innovation company with the next generation tests tells their story. The presentation will take place during the SWETOX conference […]

Malin Lindstedt, founder of SenzaGen and GARD, is awarded the NYTÄNKAREN 2017 (INNOVATIVE THINKER 2017) prize by the Swedish foundation Research Without Animal Experiments

SenzaGen’s co-founder, Professor Malin Lindstedt, has been awarded the Nytänkaren 2017 (Innovative Thinker 2017) Prize and SEK 400,000 by the Swedish fundation for Research Without Animal Experiments for her work on the development of animal-free testing methods. The prize was awarded today, 16 October at a ceremony at Research Without Animal Experiments offices in Stockholm. […]

Grundaren av SenzaGen och GARD, Malin Lindstedt, tilldelas priset som NYTÄNKAREN 2017 av stiftelsen Forska Utan Djurförsök

SenzaGens medgrundare, Professor Malin Lindstedt har tilldelats utmärkelsen Nytänkaren 2017 och 400 000 kronor av stiftelsen Forska Utan Djurförsök för sitt arbete med utveckling av djurfria testmetoder. Idag delades priset ut vid en sammankomst hos stiftelsen Forska Utan Djurförsök Stockholm Professor Malin Lindstedt får priset för sin framgångsrika utveckling av avancerade testmetoder som kan minska […]

SenzaGens vd Anki Malmborg Hager presenterar vid Swetox konferens om framtidens forskning utan djurförsök

SenzaGens vd, Anki Malmborg Hager, håller en presentation den 17 oktober med titeln: Ett nytt, djurfritt, allergitest med målsättningen att bli ”golden standard” för riskbedömning inom kosmetika- och kemikalieindustrin. Innovationsbolaget med den nya generationens tester berättar. Presentationen äger rum under SWETOX konferens på Hasselbacken i Stockholm Konferensen, Framtidens forskning med djurförsöksfria metoder, arrangeras av SWETOX […]

All laboratory elements completed in the regulatory part of the validation process for SenzaGen’s GARDskin allergy test

Lund, 6th October, 2017. SenzaGen (Nasdaq First North: SENZA) announces today that all laboratory elements in the validation of GARDskin have been completed according to plan. After data processing and statistical analysis, the results will be compiled and reported to the international regulatory authorities ECVAM and OECD. The results of the analysis will also be […]